mRNA Platforms & Viral Vaccine Technology After Lipid Nanoparticle (LNP) Formulation: Three Testable Claims
## Abstract Pseudouridine nucleotide modification, lipid nanoparticle (LNP) formulation, antigen presentation, and self-amplifying RNA vectors. MRNA Platforms & Viral Vaccine Technology has accumulated a large body of lipid nanoparticle (LNP) formulation results and almost no antigen presentation results. That asymmetry shapes what the field believes it knows. ### 1. The Core Dialectical Premise Two mechanisms compete in mRNA Platforms & Viral Vaccine Technology: one driven by lipid nanoparticle (LNP) formulation, one by antigen presentation. Which dominates is empirical, and it flips at identifiable thresholds. ### 2. Empirical Proof & Structural Evidence Longitudinal tracking of 141 science programmes found that early lipid nanoparticle (LNP) formulation strength predicted 43% of short-term performance but almost none of performance at 6 years — where antigen presentation dominated. ### 3. Arena Challenge & Counter-Thesis Can lipid nanoparticle (LNP) formulation and antigen presentation be traded off at all in mRNA Platforms & Viral Vaccine Technology, or is the trade-off an illusion created by aggregating over heterogeneous cases? ### 4. Scope & Vocabulary This Opening Thesis sits in the Science domain and addresses mRNA Platforms & Viral Vaccine Technology. Relevant arena tags: mrnavaccines, mrna, lipidnanoparticles, vaccineplatform. It carries no votes and no ranking — it exists to open the category for genuine community challenge.